Hyderabad, Jan 30, 2012: Dr. Reddy’s Laboratories wishes to clarify that the media reports highlighting its troubles with the US health authorities related to certain promotional material for Fondaparinux Sodium are misleading.

Dr. Reddy’s had received a communication from the Division of Professional Promotion (DPP), US FDA, directing for changes related to certain promotional material for Fondaparinux Sodium for Injection. The company has already addressed all matters raised by the DPP, US FDA in the letter issued on January 10, 2012. The DPP informed Dr. Reddy's Laboratories on January 24, 2012, that the matters are now considered closed.